Shots:
- InnoCare & KeyMed together have signed an exclusive license agreement with Prolium to develop & commercialize ICP-B02 (CM355)
- Prolium gains exclusive rights to develop, manufacture & commercialize ICP-B02 globally (non-oncology) and in ex-Asia regions (oncology) while InnoCare & KeyMed will get a total of ~$520M (upfront & near-term payments), minority equity stake in Prolium, clinical, regulatory & commercial milestones plus tiered royalties
- ICP-B02 (CD20×CD3 BsAb), developed by InnoCare & KeyMed, is under P-I/II trial in China for r/r NHL with early results favoring IV & SC forms, especially for FL & DLBCL. A dose expansion study combining ICP-B02 with immunochemotherapies is planned, with IND approval secured
Ref: Businesswire | Image: InnoCare & KeyMed
Related News:- Fermion Technology and Simcere Pharma Join Hands to Develop FZ002-037 for Pain Management
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
